Connect OpenTG to ChatGPT or Claude in 60 seconds

Try it

🗞️ Medical Articles Source: Science Topic: First generic twice-yearly HIV prevention injection receiv

Hakimed: Medical Resources

Hakimed: Medical Resources

@HakimApps_Guideline

Discover essential medical insights, updated medical guidelines, apps, articles, and courses. Contact: @HakimedAd For medical guidelines: @Hakimedbot Buy ads: https://telega.io/c/HakimApps_Gui

34,145 subscribers
Open in Telegram
🗞️ Medical Articles

Source: Science


Topic: First generic twice-yearly HIV prevention injection receives FDA approval

The U.S. FDA has granted tentative approval to the first generic version of lenacapavir, a long-acting injectable for HIV pre-exposure prophylaxis (PrEP), developed by India's Dr. Reddy's Laboratories. Administered twice yearly, lenacapavir offers an alternative to daily oral PrEP, with clinical trials demonstrating near-complete protection against HIV acquisition.
The generic is expected to cost approximately US$40 per person annually and could become available across 120 low- and middle-income countries covered by voluntary licensing agreements. Initial supplies are expected by the end of 2026, with broader availability in 2027. This could significantly expand access, particularly in regions with a high HIV burden, including sub-Saharan Africa.

Link: https://www.science.org/content/article/u-s-approval-cheap-generic-hiv-prevention-shot-may-boost-global-rollout

@HakimApps_Guideline
Open post in Telegram